Remuneration Information • Mar 22, 2024
Remuneration Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information ![]()
RNS Number : 8755H
Eco Animal Health Group PLC
22 March 2024
22 March 2024
ECO Animal Health Group plc
("ECO" or the "Company")
Share Awards to Executive Directors
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announced that on 21 March 2024, nominal cost conditional share options were granted under the Company's Long Term Incentive Plan (the "LTIP") over 176,652 ordinary shares in the Company (representing approximately 0.26 percent of the Company's issued share capital) to Executive Directors listed below.
| Name | Position | Number of Share Awards |
| David Hallas | Chief Executive Officer | 101,403 |
| Chris Wilks | Chief Financial Officer | 75,249 |
These awards under the LTIP are subject to performance conditions being met which have been set by the Company's Remuneration Committee and relate to Total Shareholder Return ("TSR") and Research and Development ("R&D") targets. Subject to the performance conditions being met, awards will vest after the end of a three year vesting period. Further details on the LTIP can be found in the Company's 2022 Annual Report.
-Ends-
For further information please contact:
| ECO Animal Health Group plc David Hallas (CEO) Christopher Wilks (CFO) |
020 8447 8899 |
| Singer Capital Markets (Nominated Adviser & Joint Broker) Phil Davies Sam Butcher |
020 7496 3000 |
| Investec (Joint Broker) Gary Clarence Lydia Zychowska |
020 7597 5970 |
| Equity Development Hannah Crowe Matt Evans |
020 7065 2692 |
| ICR Consilium (Financial PR) Mary-Jane Elliott Jessica Hodgson |
020 3709 5700 [email protected] |
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.
Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com
PDMR Notification - ECO LTIP Nominal Cost Conditional Share Awards
1.
Details of the person discharging managerial responsibilities / person closely associated
a.
Name
David Hallas
2.
Reason for the notification
a.
Position/status
Chief Executive Officer
b.
Initial notification
/Amendment
Initial notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
Eco Animal Health Group Plc
b.
LEI
2138009XN9DJ3YP70B55
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the
Financial instrument, type of instrument
Identification code
Options over ordinary shares of 5p each.
GB0032036807
b.
Nature of the transaction
Award of nominal cost conditional share awards under the Company's LTIP.
c.
Price(s) and volume(s)
| Price(s) | Volume(s) |
| 5p | 101,403 |
d.
Aggregated information
Aggregated volume
Price
n/a
e.
Date of the transaction
21 March 2024
f.
Place of the transaction
Outside a trading venue.
1.
Details of the person discharging managerial responsibilities / person closely associated
a.
Name
Chris Wilks
2.
Reason for the notification
a.
Position/status
Chief Financial Officer
b.
Initial notification
/Amendment
Initial notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
Eco Animal Health Group Plc
b.
LEI
2138009XN9DJ3YP70B55
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the
Financial instrument, type of instrument
Identification code
Options over ordinary shares of 5p each.
GB0032036807
b.
Nature of the transaction
Award of nominal cost conditional share awards under the Company's LTIP.
c.
Price(s) and volume(s)
| Price(s) | Volume(s) |
| 5p | 75,249 |
d.
Aggregated information
Aggregated volume
Price
n/a
e.
Date of the transaction
21 March 2024
f.
Place of the transaction
Outside a trading venue.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHFFLLLZXLFBBE
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.